Page last updated: 2024-12-08

eprodisate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eprodisate: slows the decline of renal function in AA amyloidosis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	428573
CHEMBL ID	2111092
SCHEMBL ID	34216
MeSH ID	M0510436

Synonyms (34)

Synonym
1,3-propanedisulfonic acid, 70% in h2o
propane-1,3-disulfonic acid
inchi=1/c3h8o6s2/c4-10(5,6)2-1-3-11(7,8)9/h1-3h2,(h,4,5,6)(h,7,8,9)
mgnvwudmmxzudi-uhfffaoysa-
21668-77-9
1,3-propanedisulfonic acid
eprodisate [inn]
6qfp76v7s7 ,
unii-6qfp76v7s7
eprodisate
propane-1,3-disulfonate
FT-0625314
propane-1,3-disulphonate
eprodisate [who-dd]
SCHEMBL34216
DTXSID4048301
1,3-propanesulfonic acid
MGNVWUDMMXZUDI-UHFFFAOYSA-N
1,3-propanedisulphonic acid
CHEMBL2111092
AKOS025402717
mfcd00191482
D92088
J-014224
1,3-propanedisulfonic acid (50-60% in water)
DB06405
CS-0100921
HY-128849
Q27265336
MS-23104
guanosine-5-triphosphatetetrasodiumsalt
WAA66877
STARBLD0009312
?eprodisate

Research Excerpts

Overview

Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans.

Excerpt	Reference	Relevance
"Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues."	( Eprodisate for the treatment of renal disease in AA amyloidosis. Balshaw, R; Butrimiene, I; Dember, LM; Garceau, D; Gorevic, PD; Hauck, W; Hawkins, PN; Hazenberg, BP; Lachmann, HJ; Lesnyak, O; Livneh, A; Merlini, G; Obici, L; Puéchal, X; Skinner, M, 2007)	2.5

Effects

Excerpt	Reference	Relevance
"Eprodisate has possible applicability to other types of amyloidosis; the results of a recent randomized trial showed that it may slow the progression of AA amyloidosis-related renal disease but confirmatory studies are necessary."	( Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Manenti, L; Tansinda, P; Vaglio, A, 2008)	2.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (50.00)	29.6817
2010's	5 (41.67)	24.3611
2020's	1 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	28.56 (24.57)
Research Supply Index	2.77 (2.92)
Research Growth Index	4.48 (4.65)
Search Engine Demand Index	30.30 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (28.56)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (15.38%)	5.53%
Reviews	5 (38.46%)	6.00%
Case Studies	1 (7.69%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (38.46%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dalteparin Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)	3.19	1	0
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	3.19	1	0	cyclitol; hexol
taurine [no description available]	3.19	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
tramiprosate tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA. 3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.	3.19	1	0	amino sulfonic acid; zwitterion	algal metabolite; anti-inflammatory agent; anticonvulsant; GABA agonist; nootropic agent
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	3.54	2	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
propane Propane: A three carbon alkane with the formula H3CCH2CH3.	9.1	11	2	alkane; gas molecular entity	food propellant
congo red Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.	3.42	1	1	bis(azo) compound
r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid miridesap: small molecule compound that depletes serum amyloid P component (SAP)	3.17	1	0
heparitin sulfate Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.	2.6	1	0

Condition	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	2.6	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.6	1	0
Cardiomyopathies, Primary [description not available]	2.15	1	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	8.56	10	2
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	2.15	1	0
Acute Confusional Senile Dementia [description not available]	3.01	1	0
Protein Aggregation, Pathological A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.	3.01	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.01	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	5.04	3	1
Rheumatism [description not available]	2.97	1	0
Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.	2.97	1	0
Disease Exacerbation [description not available]	4.34	1	1
Rheumatoid Arthritis [description not available]	4.34	1	1
Chronic Kidney Failure [description not available]	4.74	2	1
Benign Paroxysmal Peritonitis [description not available]	4.74	2	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	4.34	1	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	4.74	2	1
Familial Mediterranean Fever A group of HEREDITARY AUTOINFLAMMATION DISEASES, characterized by recurrent fever, abdominal pain, headache, rash, PLEURISY; and ARTHRITIS. ORCHITIS; benign MENINGITIS; and AMYLOIDOSIS may also occur. Homozygous or compound heterozygous mutations in marenostrin gene encoding PYRIN result in autosomal recessive transmission; simple heterozygous, autosomal dominant form of the disease also exists with mutations in the same gene.	4.74	2	1
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	4.74	2	1

chemdatabank.com